Vir Biotechnology Files Proxy Materials for 2024 Annual Meeting

TL;DR

Vir Bio's proxy filing is in for the 2024 annual meeting - no fee needed.

AI Summary

Vir Biotechnology, Inc. filed a Definitive Additional Materials (DEFA14A) on May 14, 2024, related to its 2024 Annual Meeting and Stockholder Engagement efforts in Spring 2024. The filing indicates no fee was required for this submission.

Why It Matters

This filing provides shareholders with important information regarding the company's annual meeting and engagement strategies, allowing them to make informed decisions.

Risk Assessment

Risk Level: low — This is a routine proxy filing for an annual meeting and does not contain significant new financial or strategic information that would immediately impact risk.

Key Players & Entities

• Vir Biotechnology, Inc. (company) — Registrant
• 0001193125-24-138206 (filing_id) — Accession Number
• 20240514 (date) — Filing Date

FAQ

From the Filing

0001193125-24-138206.txt : 20240514 0001193125-24-138206.hdr.sgml : 20240514 20240514160539 ACCESSION NUMBER: 0001193125-24-138206 CONFORMED SUBMISSION TYPE: DEFA14A PUBLIC DOCUMENT COUNT: 13 FILED AS OF DATE: 20240514 DATE AS OF CHANGE: 20240514 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Vir Biotechnology, Inc. CENTRAL INDEX KEY: 0001706431 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 812730369 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: DEFA14A SEC ACT: 1934 Act SEC FILE NUMBER: 001-39083 FILM NUMBER: 24944228 BUSINESS ADDRESS: STREET 1: 1800 OWENS STREET STREET 2: SUITE 900 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 BUSINESS PHONE: 415-906-4324 MAIL ADDRESS: STREET 1: 1800 OWENS STREET STREET 2: SUITE 900 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 DEFA14A 1 d801395ddefa14a.htm DEFA14A DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additional Materials ☐ Soliciting Material Pursuant to §240.14a-12 Vir Biotechnology, Inc. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check all boxes that apply): ☒ No fee required ☐ Fee paid previously with preliminary materials ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. 2024 Annual Meeting: Stockholder Engagement Spring 2024 © 2024 Vir Biotechnology, Inc.™ Forward-Looking Statements    Statements in this presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding the near-term financial performance of Vir Biotechnology, Inc. (the “Company” or “Vir”); the Company’s strategy and plans; capital allocation; financial and operating results and its expectations related thereto; potential of, and expectations for, the Company’s pipeline; the Company’s clinical development programs, clinical trials, including the enrollment of clinical trials, and data readouts and presentations; clinical data from the Company’s ongoing trials of tobevibart and elebsiran; the ability of tobevibart and elebsiran (as monotherapies or combination therapies) to treat and/or prevent chronic hepatitis Delta (CHD) or chronic hepatitis B virus (CHB); the Company’s preclinical pipeline; the Company’s collaboration with the Biomedical Advanced Research and Development Authority (BARDA); the Company’s use of artificial intelligence and machine learning in its efforts to engineer next-generation proteins and in other research and development efforts; the timing and amount of actual expenses, including, without limitation, the Company’s anticipated combined GAAP R&D and SG&A expenses; and the Company’s plans for its CHD, CHB, human immunodeficiency virus (HIV), RSV/MPV, Influenza, pre-cancerous HPV lesions, and COVID-19 portfolios.  Words such as “aim,” “anticipate,” “believe,” “could,” “expect,” “goal,” “intend,” “may,” “plan,” “potential,” “promising,” “will,” and similar expressions are intended to identify forward-looking statements, though not all forward